Press release
Unither Pharmaceuticals initiated the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd., a Chinese pharmaceutical company
Nanjing Ruinian Best Pharmaceutical Co. Ltd
With this acquisition, Unither is accelerating the development of its business in China, the second largest market in the world, and complementing the worldwide Unither industrial footprint in Europe, the US and Brazil. “We are delighted to welcome this company into our group. Nanjing Ruinian Best will allow us to speed up our development and strengthen our activities in China, in line with our strategy to manufacture drugs closer to our customers” said Eric Goupil, Group President of Unither.
This acquisition will allow Unither to support both Chinese and international pharmaceutical customers active in the ophthalmology and respiratory markets in China, and to offer them expertise in drug formulation and the manufacturing of sterile preservative-free single dose drugs.
Unither Pharmaceuticals
3-5 rue Saint Georges
Paris 75009
contact@unither-pharma.com
About Nanjing Ruinian Best Pharmaceutical Co. Ltd,
Nanjing Ruinian Best Pharmaceutical Co. Ltd (NRB) specializes in the development and production of solid and liquid form pharmaceutical products, with an annual revenue around EUR 10 million. It is based in Nanjing, Jiangsu Province, and has 130 employees. It is owned by Wuxi Jinyuan Industrial Investment Development Group Co. Ltd, an investment holding company located in Binhu district, in Wuxi.
About Unither Pharmaceuticals
Founded in Amiens, France, in 1993, Unither Pharmaceuticals has become the worldwide leader in drug manufacturing for leading and generic pharmaceutical companies including but not limited to, eye drop and respiratory unit doses, saline solutions, and stick packs. In March 2017, Unither was acquired by Private Equity firms Ardian, Keensight Capital and Parquest Capital, as part of a Leverage Buy-Out operation conducted with the management team.
Unither Pharmaceuticals has 6 manufacturing sites and 1 R&D center located in France, the United States and Brazil. These sites generated a revenue of € 319 million in 2019 with a headcount exceeding 1,500 employees. With the completion of this acquisition, Unither will further strengthen its position as the global leader in sterile single doses produced with Blow-Fill-Seal (BFS) technology.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Unither Pharmaceuticals initiated the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd., a Chinese pharmaceutical company here
News-ID: 2120431 • Views: …
More Releases from Unither Pharmaceuticals
Unither Pharmaceuticals has completed the purchase of the Novartis site located …
Paris (France), 12/07/2022 - Unither Pharmaceuticals, the world's leading manufacturer of sterile unit-dose products, recently acquired the Novartis plant in São Paulo, Brazil, as a new step in its industrial expansion in Brazil.
« This acquisition enables us to benefit from sterile operations in Latin America and to enlarge our offer to multidose ophthalmic containers. We are pleased to welcome the 180 people joining Unither Pharmaceuticals and bring new possibilities to…
New technology acquisition provides Unither Pharmaceuticals with specialized tra …
Preliminary clinical trials have shown that this technology would enable to lower the dosage of paracetamol while keeping the same effect as traditional dosage for oral forms.
The deal comes after previous patents acquisitions by Unither Pharmaceuticals in the last years related to oro-dispersible formulations.
This addition will further enhance Unither Pharmaceuticals capabilities to deliver innovative solutions through its recently launched ODTechTM platform, offering several solid and liquid stick packs technologies.
Unither Pharmaceuticals’…
More Releases for Pharmaceutical
Metronidazole Market 2023 Latest Innovations and Outlook By Players - Hongyuan P …
The Metronidazole Market 2023 study focuses on a global evaluation of information from the most recent market developments. The purpose of MarketsandResearch.biz is to offer the company's customers a comprehensive market overview to formulate development plans.
Designing of the report is done with the help of infographics, charts, and graphs. The report initially analyzes the various segments of the global Metronidazole market in a brief manner, which includes product types, applications.…
Hyperthyroidism Treatment Market Analytical Overview and Future | Merck, Herbran …
The Hyperthyroidism Treatment market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with development…
Mevastatin Market Is Booming Worldwide |Zhejiang Hisun Pharmaceutical, Guangdong …
Global Mevastatin Market Size research report 2022 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. This study provides information about the sales and revenue during the historic and forecasted period of (2022 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for…
Global Specialty Pharmaceutical Market Driving Future Growth on Specialty Pharma …
Global Specialty Pharmaceutical Industry Synopsis:
The Specialty Pharmaceutical Market report provides a detailed analysis of this business space. The market is analyzed in terms of production as well as consumption. Based on the production aspect, the report includes particulars pertaining to the manufacturing processes of the product, alongside revenue and gross margins of the respective manufacturers.
The Global Specialty Pharmaceutical Market will reach xxx Million USD in 2020 with CAGR xx%…
Metronidazole Market to 2023 (+5% CAGR Expected) Top Player Profiles – Hongyua …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in…
Metronidazole Market by Top Key Participant Hongyuan Pharmaceutical, Yinhe Aarti …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc.
Get Sample Copy of this Report @ https://www.researchbeam.com/global-metronidazole-2018-by-manufacturers-regions-type-and-application-forecast-to-2023-market/request-sample?utm_source=Anil
Scope of the Report:
This report focuses on the Metronidazole in global market, especially in North…
